Highlights

  • TissueCypher® research honored with a Presidential Poster Award at ACG 2025.
  • Data show the test influences personalized surveillance and treatment in Barrett’s Esophagus.
  • Findings demonstrate improved alignment of management strategies with patient-specific cancer risk.

Castle Biosciences, Inc. (NASDAQ:CSTL) presented new research at the American College of Gastroenterology 2025 Annual Scientific Meeting in Phoenix, Arizona, highlighting the ability of its TissueCypher® Barrett’s Esophagus test to deliver actionable risk assessments that inform individualized clinical decisions and enable earlier, risk-based interventions for patients with Barrett’s esophagus;.

Key Findings

Dr. Horvath’s study demonstrated that TissueCypher can identify patients at elevated risk of progression to high-grade dysplasia or esophageal adenocarcinoma—even among those diagnosed with non-dysplastic Barrett’s esophagus, a group generally considered low risk.

Two case studies revealed five-year progression probabilities of 43% and 45%, surpassing the published HGD-to-EAC progression rate of 33% over the same period. Based on these risk assessments, clinicians recommended early endoscopic eradication therapy, and both patients were later confirmed to have progressed to low-grade dysplasia.

Dr. Horvath stated, “By identifying patients at higher risk who may otherwise be missed, the TissueCypher test provides objective, individualized risk information that supports more personalized decisions around surveillance and intervention, helping clinicians act sooner to potentially reduce the risk of progression to esophageal cancer.”

Additional Research Insights

Poster P0689, presented by Ronen Arai, M.D., evaluated patients with indefinite dysplasia diagnoses—cases were inflammation obscures for accurate assessment. Two case studies showed TissueCypher high-risk results with five-year progression probabilities of 34% and 62%, prompting advanced imaging and accelerated follow-up, which led to findings of HGD and intramucosal cancer.

Poster P4930, presented by Stephen Thai, M.S., examined 114 NDBE patients from a rural Texas cohort. The test categorized patients into low-, intermediate-, and high-risk groups, influencing management in 93% of cases. High- and intermediate-risk individuals received ablation therapy, while low-risk patients safely extended surveillance intervals from 2–3 years to 5 years.

Test Background

The TissueCypher Barrett’s Esophagus test is designed to predict the likelihood of progression to HGD or EAC in patients with biopsy-confirmed BE graded as NDBE, IND, or LGD. Its performance has been validated across 14 peer-reviewed studies conducted at leading global clinical centers. The test was granted Advanced Diagnostic Laboratory Test status by the Centers for Medicare & Medicaid Services in March 2022.

About Castle Biosciences

Castle Biosciences, Inc. (NASDAQ:CSTL) is a diagnostics company focused on developing and commercializing tests that inform patient care. Its portfolio includes diagnostic solutions for skin cancers, Barrett’s esophagus, and uveal melanoma, with active development programs targeting diseases such as atopic dermatitis.